BioXcel Therapeutics (BTAI) Cash from Financing Activities (2017 - 2026)

BioXcel Therapeutics' Cash from Financing Activities history runs 10 years deep, the most recent figure standing at $232000.0 for Q1 2026.

• On a quarterly basis, Cash from Financing Activities fell 98.24% year-over-year to $232000.0 in Q1 2026; TTM through Mar 2026 was $43.5 million, a 87.42% increase from a year earlier, with the FY2025 full-year figure at $56.5 million, up 54.17% from the prior year.
• Cash from Financing Activities eased to $232000.0 in Q1 2026 per BTAI's latest filing, from $5.6 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $37.5 million in Q3 2025 and bottomed at $50000.0 in Q4 2022.
• The 5-year median for Cash from Financing Activities is $4.8 million (2024), against an average of $10.7 million.
• Across the five-year window, Cash from Financing Activities surged 42221.13% in 2022 and plunged 98.24% in 2026, its largest moves.
• Year by year, Cash from Financing Activities stood at $50000.0 in 2022, then surged by 4146.0% to $2.1 million in 2023, then surged by 101.41% to $4.3 million in 2024, then soared by 32.06% to $5.6 million in 2025, then plunged by 95.89% to $232000.0 in 2026.
• Per Business Quant, the three latest BTAI Cash from Financing Activities figures stand at $232000.0 (Q1 2026), $5.6 million (Q4 2025), and $37.5 million (Q3 2025).